News | October 12, 2009

White House Honors PET Researcher with National Medal of Science

Joanna Fowler, Ph.D., receives the National Medal of Science.

October 12, 20009 - Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science—the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

"SNM commends Joanna Fowler for her outstanding contributions to science," said Michael Graham, M.D., Ph.D., president of SNM. "Her advanced knowledge makes her stand out as one of the nation's foremost thought-leaders in nuclear medicine and molecular imaging, as well as a luminary in the quest to deliver the best patient care through the application of innovative research."

Currently serving as a senior chemist and director of the radiotracer chemistry, instrumentation and biological imaging program at the U.S. Department of Energy's Brookhaven National Laboratory in Upton, N.Y., Fowler has a long career filled with many illustrious achievements in research. Her work using the molecular imaging technique, positron emission tomography (PET) imaging, has led to significant advances in the study of how drugs, disease and aging affect the brain.

Fowler has also been instrumental in laying the groundwork for how disease is diagnosed today. In 1976, she and her colleagues synthesized 18F-fluorodeoxyglucose (FDG), a radiotracer used in PET that is widely relied on today to diagnose cancer and study brain and heart abnormalities.

Fowler's research interests are focused on how addictions cause changes to circuits in the brain. By measuring the uptake and movement of cocaine and methamphetamine in the brain, Fowler's studies have shed new light on the addictive power of drugs. She has also researched the use of PET to track the action of therapeutic drugs and explore the introduction of new drugs into the practice of medicine. Additionally, Fowler has conducted studies on how variations in a certain gene may affect personality and vulnerability to psychiatric disorders. A chief discovery from this study is that cigarette smokers have reduced levels of monoamine oxidase (MAO)—an enzyme that breaks down dopamine—the neurotransmitter that mediates reward, motivation and movement. Her work in this area could have implications for the high rate of smoking in people who suffer from depression or addiction to drugs.

Fowler has published about 350 peer-reviewed articles and holds eight patents for radiolabeling procedures. Her recognition for the distinguished National Science Award follows several other honors that she has received through the past several years, including SNM's Paul C. Aebersold Award for outstanding achievement in basic science applied to nuclear medicine, which she won in 1997.

Fowler earned a bachelor's degree in chemistry from the University of South Florida in 1964 and a doctorate in chemistry from the University of Colorado in 1967. She then went on to conduct postdoctoral research at the University of East Anglia in Norwich, England. She joined Brookhaven Laboratory in 1969 and has been conducting research there since that time.

The National Medal of Science was created in 1959 and is administered by the National Science Foundation. The award is given annually to individuals who have made outstanding contributions to science and engineering. Nominees are selected by a committee of Presidential appointees. Nominees are selected based on advanced knowledge and contributions to the biological, behavioral/social and physical sciences, as well as chemistry, engineering, computing and mathematics.

For more information:

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init